Responses
Regular and young investigator award abstracts
Clinical trials in progress
345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
Compose a Response to This Article
Other responses
No responses have been published for this article.
